TGFB2 and gastric cancer: The high responsiveness of ICB when TGFβ2 is highly expressed suggests that the detection of TGFβ2 expression can predict the response of gastric cancer patients to immune checkpoint inhibitors and may serve as a candidate target for gastric cancer immunotherapy.